GlassScriptPhysician profile
James Carroccio
NPI 1922210228
$14,073.12
in general payments reported to CMS, 2019-2025
61 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,025 · 2020: $1,646 · 2021: $1,962 · 2022: $1,524 · 2023: $2,448 · 2024: $2,318 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,911 · Education: $5.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,910.60 |
| Education | $5.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,153.88 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Astrazeneca Pharmaceuticals LP | $1,375.55 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,248.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,045.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $891.25 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $569.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $524.25 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.21 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $438.60 | 2019-2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $435.35 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $380.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $365.92 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Astellas Pharma US INC | $340.57 | 2020-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $307.65 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $298.46 | 2019-2024 | Austedo Xr, Austedo, Airduo Digihaler |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carroccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.